Compare Stocks → How Biden has already won 2024 (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:INVVYNASDAQ:KALANASDAQ:KURANASDAQ:MTEMNASDAQ:NXTC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsKALAKALA BIO$6.83-3.5%$7.32$5.10▼$19.35$19.23M-1.7523,436 shs702 shsKURAKura Oncology$20.77+1.1%$20.63$7.41▼$24.17$1.58B0.891.26 million shs422,284 shsMTEMMolecular Templates$1.55-3.1%$2.14$1.40▼$9.45$10.20M1.1551,965 shs60,981 shsNXTCNextCure$1.72+8.9%$1.72$0.98▼$2.57$48.11M0.54226,109 shs161,477 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVVYIndivior0.00%0.00%0.00%0.00%-18.18%KALAKALA BIO+2.31%+1.87%-7.09%+2.02%-54.06%KURAKura Oncology-2.49%+1.31%+0.61%+1.06%+80.22%MTEMMolecular Templates-0.62%-3.03%-19.19%-54.42%-76.39%NXTCNextCure0.00%+15.33%-22.93%+21.54%-9.20%Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINVVYIndiviorN/AN/AN/AN/AN/AN/AN/AN/AKALAKALA BIO4.0419 of 5 stars3.55.00.04.41.70.80.0KURAKura Oncology3.2531 of 5 stars3.42.00.04.71.80.00.0MTEMMolecular Templates0.9166 of 5 stars0.02.00.04.60.64.20.0NXTCNextCure4.5062 of 5 stars3.55.00.04.61.11.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINVVYIndiviorN/AN/AN/AN/AKALAKALA BIO3.00Buy$18.00163.54% UpsideKURAKura Oncology2.88Moderate Buy$28.2836.15% UpsideMTEMMolecular TemplatesN/AN/AN/AN/ANXTCNextCure3.00Buy$6.00248.84% UpsideCurrent Analyst RatingsLatest KALA, NXTC, MTEM, KURA, and INVVY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2024KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$32.005/3/2024KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.005/3/2024KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$37.005/3/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/3/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.004/22/2024KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.004/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.003/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/6/2024KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00(Data available from 5/9/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07KALAKALA BIO$3.89M4.94N/AN/A$2.79 per share2.45KURAKura OncologyN/AN/AN/AN/A$5.35 per shareN/AMTEMMolecular Templates$57.31M0.18N/AN/A$0.78 per share1.99NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/AKALAKALA BIO-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)KURAKura Oncology-$152.63M-$2.17N/AN/AN/AN/A-37.52%-34.11%8/1/2024 (Estimated)MTEMMolecular Templates-$8.12M-$1.55N/AN/AN/A-14.18%-9,335.53%-20.51%5/20/2024 (Estimated)NXTCNextCure-$62.72M-$2.28N/AN/AN/AN/A-53.29%-47.52%8/1/2024 (Estimated)Latest KALA, NXTC, MTEM, KURA, and INVVY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024Q1 2024KURAKura Oncology-$0.56-$0.59-$0.03-$0.59N/AN/A 3/29/2024Q4 2023KALAKALA BION/A-$3.18-$3.18-$3.18N/AN/A3/29/2024Q4 2023MTEMMolecular Templates-$2.10-$0.73+$1.37-$0.73N/A$7.02 million3/21/2024Q4 2023NXTCNextCure-$0.54-$0.52+$0.02-$0.52N/AN/A2/27/2024Q4 2023KURAKura Oncology-$0.56-$0.55+$0.01-$0.55N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINVVYIndiviorN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINVVYIndiviorN/AN/AN/AKALAKALA BIO5.106.336.33KURAKura Oncology0.0216.6716.67MTEMMolecular TemplatesN/A0.970.97NXTCNextCureN/A10.7010.70OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINVVYIndivior0.05%KALAKALA BIO24.61%KURAKura OncologyN/AMTEMMolecular Templates95.47%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipINVVYIndiviorN/AKALAKALA BIO13.40%KURAKura Oncology5.50%MTEMMolecular Templates13.40%NXTCNextCure11.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableINVVYIndivior800137.88 millionN/ANot OptionableKALAKALA BIO432.82 million2.44 millionNot OptionableKURAKura Oncology14276.18 million71.99 millionOptionableMTEMMolecular Templates626.58 million5.70 millionNo DataNXTCNextCure8227.97 million24.64 millionOptionableKALA, NXTC, MTEM, KURA, and INVVY HeadlinesSourceHeadlineHC Wainwright Reiterates Buy Rating for NextCure (NASDAQ:NXTC)americanbankingnews.com - May 7 at 6:22 AMNeedham & Company LLC Reiterates "Buy" Rating for NextCure (NASDAQ:NXTC)americanbankingnews.com - May 7 at 6:22 AMBuy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid Financialsmarkets.businessinsider.com - May 4 at 4:22 AMNXTC Stock Earnings: NextCure Misses EPS for Q1 2024investorplace.com - May 2 at 10:03 PMNextCure Provides Business Update and Reports First Quarter 2024 Financial Resultsglobenewswire.com - May 2 at 4:05 PMNextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024globenewswire.com - April 24 at 4:05 PMPromising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy Ratingmarkets.businessinsider.com - April 8 at 7:06 PMNextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024globenewswire.com - April 8 at 7:00 AMNextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Boardglobenewswire.com - April 4 at 7:05 AMNextCure to Present at 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 7:00 AMWill NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?finance.yahoo.com - March 27 at 10:07 AMWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Richinvestorplace.com - March 23 at 6:00 AMPromising Clinical Trial Results for NextCure’s NC410 Bolster Buy Ratingmarkets.businessinsider.com - March 22 at 5:19 PMAnalysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)markets.businessinsider.com - March 21 at 9:15 PMNextCure to Cut 37% of Jobs, Will Narrow Focus on Drug Candidatesmarketwatch.com - March 21 at 4:06 PMNextCure to lay off 37% of staff, dial back research plansbiopharmadive.com - March 21 at 4:06 PMMd. biopharma lays off staff, pauses manufacturing to preserve cashbizjournals.com - March 21 at 4:06 PMNextCure Provides Business Update and Reports Full Year 2023 Financial Resultsglobenewswire.com - March 21 at 8:55 AMNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advancesglobenewswire.com - March 5 at 8:05 AMNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disordersfinance.yahoo.com - January 18 at 6:56 PMNextCure Stock (NASDAQ:NXTC) Dividends: History, Yield and Datesbenzinga.com - December 28 at 3:49 PMHere's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishingfinance.yahoo.com - December 25 at 2:02 PMNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injuryfinance.yahoo.com - December 21 at 7:59 AMNextCure (NXTC) Down on Shelving Plans to Develop Candidatefinance.yahoo.com - December 15 at 1:35 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIndiviorOTCMKTS:INVVYIndivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Kura OncologyNASDAQ:KURAKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Molecular TemplatesNASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.